Zentalis Pharmaceuticals, Inc. ZNTL
1.78 USD -0.07 (-3.78%)
At closeNov 4, 2026, 5:16 AM EST
1.84 +0.06 +3.37%
Pre-market · Nov 4, 5:16 AM ET
1.75 Day range 1.96
1.21 52-week range 6.95
- YTD
- +31.85%
- 1 year
- +23.61%
News
globenewswire.com Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
globenewswire.com Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
benzinga.com Zentalis Pharmaceuticals Presents Data From Its Interim Analysis Of DENALI Part 1b Trial At ESMO Congress 2026 Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven…
globenewswire.com Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
defenseworld.net HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday, Marketbeat.com reports.…
benzinga.com HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy and maintains $10 price target.
globenewswire.com Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
defenseworld.net Johnson & Johnson (NYSE:JNJ) & Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head-To-Head Contrast Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) and Johnson and Johnson (NYSE: JNJ - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the…
defenseworld.net Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL) Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
defenseworld.net Leerink Partners Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock analysts at Leerink Partners started coverage on shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) in a report released on Monday, MarketBeat reports. The firm set an…
benzinga.com Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8 Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.
globenewswire.com Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
benzinga.com This Small Biotech's Cancer Drug Could Reach $1.3 Billion In Peak Sales Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) received a bullish initiation from William Blair on Tuesday, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug,…
benzinga.com This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.- benzinga.com William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.
seekingalpha.com Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL BlackRock Inc. acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) during the second quarter, according to the company in its most recent filing with the Securities and Exchange…
globenewswire.com Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
globenewswire.com Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
seekingalpha.com Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target…
benzinga.com Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.
globenewswire.com Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report…
globenewswire.com Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…
globenewswire.com Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an…
globenewswire.com Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 Enrollment completed in Part 2a and 2b of the DENALI trial; Part 2c is enrolling DENALI…
globenewswire.com Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
benzinga.com ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Nasdaq Moves Higher; US Inflation Rate Accelerates In March U.S. stocks mixed, Nasdaq up 100 points. Inflation rate surges to 3.3%. Japan's Nikkei 225 and China's Shanghai Composite close higher.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Organon, CoreWeave, WhiteFiber And Other Big Stocks Moving Higher On Friday Dow Jones fell 100 points as Sun Pharma offered 12 billion to buy Organon, Organon shares jumped 26.4%, other stocks also rose.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 236 companies hit new 52-week lows.